

ORIGINAL ARTICLE

Synergistic antitumor effect of resveratrol and sorafenib on hepatocellular carcinoma through PKA/AMPK/eEF2K pathway

Meili Gao*, Chun Deng and Fan Dang

Department of Biological Science and Engineering, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China

Popular scientific summary

- Resveratrol potentiates the inhibited proliferation of sorafenib in hepatocellular carcinoma cells.
- Resveratrol and sorafenib combination treatment synergistically increased cells in S phase and apoptotic cells.
- Combination of resveratrol and sorafenib have synergetic effect in reducing the PKA/AMPK/eEF2K pathway and inhibiting the tumor *in vivo*.

Abstract

Although sorafenib (Sor) is the only effective drug for hepatocellular carcinoma (HCC), its therapeutic potential to date is mainly limited to the low tumor response. This study was designed to explore whether resveratrol (Res) could potentiate the anticancerous activity of Sor. We used HepG2 and Huh7 HCC cell lines and BALB/c nude mice for *in vitro* and *in vivo* studies, respectively. The cultured cell lines and tumor induction in the mice were treated with different concentrations of Res and Sor alone, and the combination of Res and Sor to observe the antitumor effects. Significant inhibitory effects were observed in the combined treatment of Res and Sor compared to Res and Sor alone treatments both *in vitro* and *in vivo* as demonstrated by significantly high number of S phase cells and apoptotic cells. Moreover, these findings were accompanied by the reduction of CDK2, CDC25A, PKA, p-AMPK, and eEF2K protein levels and the increment of cyclin A, cleavage caspase-3, caspase-8, and caspase-9 protein levels. The combinational treatment exhibited more significant anticancerous effect than the Res and Sor alone treatments in mice-bearing HepG2 xenograft. Overall, our results suggest that PKA/AMPK/eEF2K pathway is involved in the synergistic anticancerous activity of Res and Sor combination treatment in HCC cells. Thus, Res and Sor combination therapy may be promising in increasing the tumor response of Sor in the future.

Keywords: *hepatocellular carcinoma; resveratrol; sorafenib; PKA/AMPK/eEF2K pathway*

Received: 3 June 2019; Revised: 31 March 2021; Published: 13 October 2021

As one of the most common malignancies, hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide (1). It represents the most common histological subtype and accounts for 90% liver cancers (2, 3). HCC is predominant in Asian countries, including China, Mongolia, Southeast Asia, Sub-Saharan Western, and Eastern Africa (4). In China, due to the high prevalence of HBV, HCC is the second most common cause of cancer-related mortality with an estimated 598,000 deaths annually (5, 6).

Using screening programs for earlier diagnosis has shown that most HCC patients are at the intermediate- or advanced-stage of the disease (2, 5, 6). For these

HCC patients, transcatheter arterial chemoembolization (TACE) and the multi-kinase inhibitor of sorafenib (Sor) are the two approved therapies (7). As a novel diaryl urea compound, Sor has shown the antiproliferative effects in HCC cell lines. It also decreased the tumor angiogenesis and tumor-cell signaling, while increased the apoptosis in a mouse model (2). Sor is the only approved systemic therapy to improve overall survival (OS) in patients with advanced HCC (1, 5, 8, 9). Currently, Sor is the first-line treatment available for stage C patients of Barcelona Clinic Liver Cancer (BCLC) (10). However, the therapeutic potential of Sor is limited to the high cost, low tumor response and the significant side effects (11, 12). Thus,

there is a need to find an effective neo-adjuvant to enhance the tumor response and to reduce the side effects of Sor.

Resveratrol (trans 3',4',5'-trihydroxystilbene, Res) is a polyphenol compound, which can be found naturally in food and beverage. It is widely recognized as one of the health-promoting components (13, 14). Res has anticancerous activity at multiple stages of tumor development and progression as well as minimal toxicity to normal cells (15, 16). In addition, studies have shown that Res enhances both growth inhibition and cytotoxic activities of several chemotherapeutic agents, including daunorubicin and doxorubicin (DOX), with negligible side effects on normal cells (17, 18). Moreover, it has been shown that Res sensitized the aerobic glycolytic HCC cells to Sor for inducing mitochondria-associated apoptosis through reducing hexokinase 2 (HK2) expression (15).

Recent studies suggest that Res inhibits HCC cell lines' proliferation through AMP-activated protein kinase (AMPK) activation (19, 20). AMPK plays a central role in cellular energy homeostasis and serves as an essential regulator of metabolic activities in controlling tumor cell growth and proliferation (21, 22). AMPK activation is required for the phosphorylation by protein kinase A (PKA), which has been indicated to regulate many aspects of cell functions, including signal transduction, metabolism, and gene expression (23, 24). The eukaryotic elongation factor 2 kinase (eEF2K) is one of the downstream molecule of AMPK signal pathway and is a CaM-dependent protein kinase III. It phosphorylates and inhibits the function of the eukaryotic elongation factor 2 (EEF2), thus regulating translation and protein synthesis (25, 26). There are papers that have investigated the effects of Sor on AMPK-associated signaling pathways, such as NAD/SIRT1/AMPK axis, AKT and AMPK phosphorylation, TFAM and AMPK, ATP-AMPK-mTOR-SREBP1, and NOD2-AMPK (27–31). However, the combined effects of Res and Sor on the PKA/AMPK/eEF2K signaling pathway during the HCC cell proliferation have not been analyzed to date. Here, we examined whether Res can enhance the inhibitory effect of Sor on HCC cell lines through PKA/AMPK/eEF2K pathway *in vitro* and *in vivo*.

Materials and methods

Materials

Res was purchased from LC Laboratories (Woburn, MA, USA). Sor was purchased from Selleck Chemicals (Houston, TX, USA). RPMI 1640 medium and fetal bovine serum (FBS) were purchased from Hyclone (GE Healthcare, USA). Cell Counting Kit-8 (CCK-8) was obtained from Dojin Chemical Co. (Kumamoto, Japan). Annexin V-FITC/propidium iodide (PI) apoptosis assay kit was bought from Roche (Roche, USA). PI and other reagents were purchased from Sigma-Aldrich (Sigma, USA).

Antibodies to CDK2, CDC25A, CyclinA, caspase-3, caspase-8, caspase-9, PKA, eEF2K, p-AMPK, and AMPK were purchased from Cell Signaling Technology (Massachusetts, USA).

Cell culture and treatment

Human HCC cell lines of HepG2 and Huh7, which were authenticated by short tandem repeat (STR) method, were purchased from the cell bank of the Chinese Academy of Science (Shanghai, China). HepG2 and Huh7 were grown in RPMI 1640 medium supplemented with 10% FBS, 100 units/mL penicillin, and 100 mg/mL streptomycin. Cells were incubated in a humidified atmosphere of 5% CO₂ at 37°C.

Based on the previous published studies (14, 15), for the cell viability assay, HepG2 and Huh7 cell lines were treated with Res and Sor at the concentration of (0, 0.1, 1, 10, 20, 40, 80, and 100 μM) and (0, 2.5, 5, 10, 20, 40, 80, and 100 μM), respectively, for 24, 48, and 72 h. For the combination treatment, 80 μM concentration of Res was selected and combined with 2.5, 5, and 10 μM Sor, and the cells were treated for 48 h.

Cell viability assay

Cell viability was determined by the CCK-8 method according to the manufacturer's instructions. Cells were plated and treated with Res and Sor alone, and combination treatment of Res and Sor at different concentrations as described earlier. After incubation, 10 μL of CCK-8 was added to each well and measured absorbance at 450 nm using a Multimode Microplate Reader. Cell viability was calculated from the optical density readings of different treatment groups.

Cell cycle analysis

After treatment with Res and Sor alone, and in combination treatment for 48 h, HCC cell lines were harvested, washed with PBS, and fixed in 80% ethanol at -20°C overnight. Then, the cells were centrifuged, washed with phosphate buffered saline (PBS), and permeabilized with 0.25% Triton X-100. Furthermore, the cells were incubated with PI (20 μg/mL) supplemented with RNase A (50 μg/mL) for 30 min at room temperature. The relative DNA content was assayed using a BD FACSVerser (BD Biosciences, Heidelberg, Germany) flow cytometer. Cell cycle distribution was analyzed using the FCSExpress 4 Flow Research software.

Cell apoptosis assay

To determine cellular apoptosis, an Annexin V-FITC apoptosis detection kit with PI was used according to the manufacturer's instructions. In brief, HCC cells were harvested and washed twice with cold PBS and resuspended in 500 μL binding buffer. Thereafter, the cells were mixed with

5 μ L annexin V-FITC and 5 μ L PI for 15 min in the dark. The Fluorescence Activating Cell Sorter (FACS) caliber flow cytometer (BDFACS Canto II, BD Biosciences) and modft software were used to analyze the apoptotic cells.

Western blotting analysis

Regulatory proteins were analyzed by western blotting technique. Western blotting was carried out using the standard protocol. Briefly, cell lysate was prepared in Radio-Immunoprecipitation Assay (RIPA) lysis buffer. Membranes were incubated with primary antibodies overnight at 4°C. Then, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody, probed using enhanced chemiluminescence (ECL) western blotting detection system (Millipore, MA, USA), and visualized using the BioSpectrum AC imaging system.

In vivo xenograft experiments

Animal experiments were performed according to the protocols approved by the Animal Care and Use Committee of Xi'an Jiaotong University. Female BALB/c (*nu/nu*) mice, 5–6 weeks old, were purchased from Experimental Animal Center of Xi'an Jiaotong University (Shaanxi Province, China). The mice were housed with a light/dark cycle of 12/12 h and allowed free access to rodent chow and water. HepG2 cells were cultured and harvested, washed with PBS, and resuspended in PBS. After anesthetization, 5×10^6 /mL cells were injected subcutaneously into the posterior hind flank region of mice. When the tumor masses became established and palpable, the mice were randomly divided into four groups as follows: control (Con, treatment vehicle of 0.9% sodium chloride plus 1% dimethylsulfoxide (DMSO)), Res (20 mg/kg, dissolved in vehicle) alone (22), Sor (25 mg/kg, dissolved in vehicle) alone (32), or combination treatment of Res (intraperitoneal injection) and Sor (oral administration) twice per week for 3 weeks. Tumor volumes and body weights were measured, and the relative volumes and weights were indicated in the experiment. A TUNEL and DAPI staining was used to assay the apoptotic cells in tumor.

Statistical analysis

Data are expressed as mean \pm standard deviation (SD) of at least three independent experiments. We used Student's *t*-test and Prism 5 software. Differences were considered significant at a *P*-value of <0.05 .

Results

Antiproliferative activity of Sor and Res in HCC cell lines

Cell proliferation was presented as the value of cell viability. The effects of Res and Sor alone on cell viability of HepG2 and Huh7 cell lines are shown in Fig. 1a, b, respectively. The cell viability was significantly decreased

($P < 0.001$) at 80 and 100 μ M Res treatment in HepG2 cells for 72 h. Sor treatment significantly decreased ($P < 0.01$ and $P < 0.001$) the cell viability at 2.5–100 μ M for 24–72 h in Huh7 cells compared to the control cells (0 μ M). Based on the inhibitory effects of Res and Sor treatments alone, the combination treatment of Res (80 μ M) and Sor (2.5, 5, and 10 μ M) was carried out and assayed for 48 h (Fig. 1c). Significant synergistic antiproliferative effects ($P < 0.05$, $P < 0.01$, and $P < 0.001$, respectively) on the cells were observed in comparison with the corresponding Res and Sor treatments alone.

Res enhances induction of S phase arrest and reduction of associated regulatory proteins by Sor in HCC cell lines

Distribution of cells in various phases of cell cycle after treatment with Res at 80 μ M, Sor at 2.5, 5, and 10 μ M, and Res combined with Sor for 48 h is shown in Fig. 2. Representative photographs (Fig. 2a, b) show notably decreased cells at G0/G1 phase, whereas notably increased cells at S phase in HepG2 and Huh7 cell lines after 80 μ M Res treatment (Fig. 2c). Sor treatment slightly decreased cells at G0/G1 phase and increased cells at S phase in both HCC cell lines. Notable decrease at G0/G1 phase and an obvious accumulation of cells at S phase were observed after combined treatment of Res and Sor for 48 h in both cell lines compared to the Res and Sor alone treatments (Fig. 2c).

Regulatory proteins of CDK2, CDC25A, and cyclin A were shown as in Fig. 3a. Levels of CDK2 and CDC25A proteins were decreased, and for cyclin A, they were increased after Res or Sor treatment alone, and combined treatment in the HCC cell lines (Fig. 3b–d). Significant reductions or increments were also observed in combination treatment for these regulatory proteins ($P < 0.05$ and $P < 0.001$) compared with the Res and Sor alone treatments (Fig. 3b–d). The results showed cell cycle arrest at S phase, and this effect was partly associated with CDK2, CDC25A, and cyclin A proteins.

Res enhances apoptosis and activate caspase-3, caspase-8, and caspase-9 proteins in Sor-treated HCC cell lines

To determine whether Res could enhance the apoptosis induced by Sor, HepG2, and Huh7, cells were treated with Res, Sor, and combination of Res and Sor, then stained with annexin V-FITC and PI, and analyzed by flow cytometry (Fig. 4a, b). The percentage of apoptotic cells (all annexin V-FITC staining cells) was significantly increased ($P < 0.001$, Fig. 4c) in both cell lines after Res, Sor, and combination treatments. Especially, combination treatment group resulted in significant increments ($P < 0.001$) in apoptotic cells compared with Res and Sor alone treatment groups.

Cleaved caspase-3, caspase-8, and caspase-9 protein levels (Fig. 5a) were significantly increased in both cell lines after treatment with Res and Sor alone for 48 h (Fig. 5b–d), except cleaved caspase-8 in Huh7 cells treated




Fig. 1. Inhibitory effect of Res, Sor, and Res combination with Sor treatments on proliferation in HepG2 and Huh7 cells. The CCK-8 method was used to assay the cell proliferation, which expressed as cell viability. HepG2 (a) and Huh7 (b) cells were treated at 0–100 μM of Res and Sor alone for 24, 48, 72 h. (c) 80 μM Res combination 2.5–10 μM Sor combination treatment for 48 h in HepG2 and Huh7 cells. Data are expressed as mean ± SD ($n = 3$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$ versus the control group. ### $P < 0.001$ versus Res treatment group. $^{\$}P < 0.05$, $^{SS}P < 0.01$, and $^{SS\$}P < 0.001$ versus the corresponding Sor treatment group.




Fig. 2. Inhibitory effect of Res, Sor, and Res combination with Sor treatments on cell cycle. (a, b) Cells were harvested, stained with PI, and subjected to flow cytometry at an interval of 6 h, and representative photographs were shown ($n = 3$). (c) The variation mean values of different phases of cell cycle distribution.




Fig 3. The cell cycle regulatory proteins of CDC 25A, CDK2, and cyclin A in HepG2 and Huh7 cells. (a) The representative photograph of western blotting. (b–d) Analysis of results. Data are expressed as mean \pm SD ($n = 3$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$ versus the control group. # $P < 0.05$ and ### $P < 0.001$ versus Res treatment group. $^{\$}P < 0.05$, $^{\$\$}P < 0.01$, and $^{\$ \$ \$}P < 0.001$ versus the corresponding Sor treatment group.




Fig. 4. Inhibitory effect of Res, Sor, and Res combination with Sor treatments on apoptosis in HepG2 and Huh7 cells. (a, b) Representative photographs of annexin V-FITC/PI assay to identify apoptotic cells. (c) Analysis of the apoptotic cells (all annexin-V positive cells). Data are expressed as mean \pm SD ($n = 3$). *** $P < 0.001$ versus the control group. ### $P < 0.001$ versus Res treatment group. SSS $P < 0.001$ versus the corresponding Sor treatment group.




Fig 5. Induction of the apoptotic proteins of cleavage caspase-3, caspase-8, and caspase-9. HepG2 and Huh7 cells were treated with 0 μ M (Con.), 80 μ M Res, Sor at the concentrations of 2.5, 5, and 10 μ M, and Res combination different concentrations of Sor for 48 h. (a) Representative photograph of western blotting. (b–d) Analysis of results. Data are expressed as mean \pm SD ($n = 3$). ** $P < 0.01$ and *** $P < 0.001$ versus the control group. # $P < 0.05$ and ### $P < 0.001$ versus Res treatment group. $^S P < 0.001$ and $^{SSS} P < 0.001$ versus the corresponding Sor treatment group.

with Res, cleaved caspase-9 in both HCC cell lines treated with Res, and in HepG2 cells treated with 2.5 μM Sor. The levels of above-mentioned increased proteins were further enhanced significantly ($P < 0.05$ and $P < 0.001$) in the combination treatment of Res and Sor in both cell lines compared with Res and Sor alone treatments.

Res reduces the expression of PKA, eEF2K, and p-AMPK proteins in Sor-treated HCC cell lines

As shown in Fig. 6, the protein levels of eEF2K were significantly decreased after 5 and 10 μM Sor and combination treatments compared with the untreated cells (Con.) for 48 h. Protein levels of PKA and eEF2K were markedly decreased ($P < 0.05$ and $P < 0.001$) in the combination treatment compared to the Res and Sor alone treatments. The ratio of p-AMPK/AMPK showed a marked reduction ($P < 0.05$, $P < 0.01$, and $P < 0.001$) in single Res and Sor alone treatments, and combination treatment of Res and Sor in both HCC cell lines compared to the untreated cells (Con.), respectively. Similarly, the combined treatment of Res and Sor showed a significant reduction ($P < 0.05$ and $P < 0.001$) in this ratio compared with the Res and Sor alone treatments.

Res along with Sor synergistically enhances the inhibition of tumor growth in vivo

The synergistic effect of Res on Sor to inhibit the tumor growth was evaluated *in vivo*. HepG2 cells were used to generate tumor xenografts in BALB/c nude mice (Fig. 7a). The relative tumor volumes and tumor weights were decreased after Res and Sor alone treatments, and simultaneous combined treatment compared with control group. The relative tumor volumes and tumor weights were significantly decreased ($P < 0.05$) in combination treatment compared to Res and Sor alone treatments (Fig. 7b, c). The apoptotic effect was assayed by TUNEL and DAPI staining. As shown in Fig. 7d, combination treatment notably induced apoptosis in cells compared with Res and Sor alone treatment groups. The findings demonstrate that Res may enhance the ability of Sor to inhibit tumor growth *in vivo*.

Based on the previous findings, the possible mechanism of Res combined with Sor treatment in HCC was demonstrated as Fig. 7e.

Discussion

The antiproliferative and apoptotic activities of Sor and Res alone have been observed in a wide variety of tumor cell types, including HCC cells. Scanty literature is available about the combined effect of Res and Sor on HCC cell lines and its mechanism. In this study, we evaluated and compared different aspects of HCC cell lines via *in vitro* and *in vivo* experiments using Res and Sor alone treatments, and combination treatment.

We found that 80–100 μM Res treatment induced significant inhibition of cell viability for 72 h. This finding is supported by Dai et al. who demonstrated significant inhibition of cell viability in HCC-LM3, Bel-7402, and Huh-7 cell lines after treatment with Res at 80 μM for 24 h (15). Similarly, Sor, the only approved systemic therapy in HCC patients (1, 5), induced significant inhibition of cell viability in HepG2 and Huh7 cell lines after treatment for 24–72 h. Under combination treatment, significant inhibition of cell viability was observed compared to Res and Sor alone treatments in HePG2 and Huh7 cell lines. This suggests that Res could potentiate the inhibitory effect of Sor on HCC cell proliferation. These findings are consistent with a previous study that indicated significant inhibition of cell viability after 20 μM Res and 5 μM Sor combination treatment for 24 h in HCC-LM3 and Bel-7402 (15). Similarly, significant inhibitory effects on cell viability have been observed for Res and Sor combination treatments in renal carcinoma cell lines of Caki-1 and 786-O (16) and breast cancer cell line of MCF-7 (12).

The antiproliferative effects of these drugs could be due to their action on cell cycle. We observed that there was a significant increase in S phase cells in both cell lines after treatment with 80 μM Res. This has previously been demonstrated that where S phase was arrested after 10 $\mu\text{g/mL}$ Res treatment in Huh7 cell (32). We also observed that the percent of S phase cells was increased, though the percent of G0/G1 cells was decreased in both HCC cell lines after Sor treatment. These findings are in agreement with previous findings about the effect of Sor on cell cycle distribution in HepG2 and Huh7 cell lines (33, 34). However, another study has shown that Sor treatment for 24 h resulted in cell-cycle arrest with a proportional increase in G0–G1 phase and a decrease in S phase in Hep 3B, Hep G2, SK-Hep1, and Huh7 cell lines (35). These findings suggest that the cell cycle alterations are dependent on cell types and treatments (33). Our results also implied that the DNA synthesis was retarded (33). The effect of cell cycle arrest at S phase was very prominent in the combined treatment group, which proved the evidence of Res working synergistically with Sor in cell cycle arrest. Deregulated cell cycles often occur in cancer cells and consequently are a target for cancer drugs (36). Thus, combination treatment of Res with Sor suggests its potential use as anticancerous drugs. Corresponding to the changes of the cell cycle distribution, reduction in CDC25A and CDK2 proteins, thus, suggests the inhibitory effects these drugs on CDK2/cyclin A. These findings are consistent with previous studies where Res treatment caused a reduction in cyclin E and CDK2 expression (32) and Sor treatment reduced levels of CDC25A in HepG2 cell (37). CDC25A plays an important role in cell proliferation by interacting with cyclin A/CDK2 complex to promote S phase cell cycle progression. The decrease in




Fig. 6. Downregulation effect of Res, Sor, and Res combination with Sor treatment on PKA/AMPK/eEF2K signal in HepG2 and Huh7 cells. Single 80 μ M Res, 2.5–10 μ M Sor, and combination of Res and Sor treatments for 48 h in HepG2 and Huh7 cells. Western blotting analysis to determine the expression of PKA, p-AMPK/AMPK, and eEF2K proteins. Data are expressed as mean \pm SD ($n = 3$). * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$ versus the control group. # $P < 0.05$ and ### $P < 0.001$ versus Res treatment group. ^S $P < 0.05$ and ^{SSS} $P < 0.001$ versus the corresponding Sor treatment group.




Fig. 7. Inhibition of Res, Sor, and Res combination with Sor on HepG2 xenograft growth and on apoptosis in vivo. (a) A representative photograph of a tumor at the end of the experiment. (b, c) The relative tumor volume and tumor weight, respectively. (d) Representative merge photographs of apoptotic cells detected with TUNEL and DAPI staining (200×) in the different groups. (e) Schematic representation of the mechanism of Res combined with Sor on HCC cells. Data are presented as the mean \pm SD, * $P < 0.05$ and *** $P < 0.001$ versus Con group. # $P < 0.05$ versus Res group. $^S P < 0.05$ versus Sor group. (e) Possible mechanism of combination of Res and Sor on HCC cells.

CDK2 activity may be due to the CDC25A degradation, which is likely to contribute to the S-phase checkpoint (38, 39). Therefore, the results of the regulatory proteins may further confirm the variations at G0/G1 and S phases. The findings suggest the CDC25A-cyclin A/CDK2 signaling pathway involvement in S phase arrest after Res and Sor combination treatment in HCC cell lines.

We further investigated Res and Sor alone, and combination treatments on the apoptotic effects. Annexin V/PI double staining assay indicated Res and Sor alone treatments-induced apoptosis in HCC cells, but this phenomenon was much more prominent in the combined treatment groups. Our findings are in line with other studies where Res and Sor alone treatments have been demonstrated to be effective in suppressing HCC cells proliferation and inducing apoptosis (15, 32, 34, 37). Res has also been reported to enhance the effect of Sor on the induction of apoptosis in renal carcinoma cell line of 786-O and in breast cancer cell line of MCF-7 (12, 16). Notably, combination treatment can synergistically increase the cleavage of caspase-3, caspase-8, and caspase-9 compared to Sor and Res alone treatments. The apoptotic caspases, including caspase-3, caspase-8, and caspase-9, play a crucial role in the regulation of programmed cell death (40). Our results confirm the synergistic enhancement of apoptosis induced by combined treatment with Res and Sor through the activation of caspase cascade signal as reported in 786-O and MCF-7 cell lines (12, 16).

In our study, we found that Res and Sor alone, and combination treatments decreased the expression of PKA, p-AMPK, and eEF2K, but did not affect AMPK levels. Our results suggest the AMPK signal inactivation through the decrease in the levels of PKA, p-AMPK, and eEF2K. However, significant increment of resveratrol (50 μ M) on phospho-AMPK in hepG2 cells (20), no significant effects of resveratrol (5 μ M) on H4-II-E cells (19), were observed in published studies. This may be due to the concentrations and cells used differently in these studies. Similarly, Sor-induced activation of AMPK through phosphorylation has been demonstrated in most HCC or liver cancer (32–36, 41); there is a study that found a significant decrease after the combination treatment of arsenic trioxide (ATO) and Sor in AMPK activation in comparison to ATO treatment alone (42). This may be due to the status of low AMPK activation in HepG2 and huh7 cell lines that coordinate with other kinases to promote cell survival (43). It is worth noting that Sor alone and combination treatments notably decreased the expression of eEF2K level in our study. The activity of eEF2K was associated with proliferation, migration, and invasion rates. High expression or overexpression of eEF2K has been showed in malignant cancers. Downregulation of expression or silencing of eEF2K has been demonstrated the inhibition of proliferation, migration, and invasion in many

cancer cell lines (44, 45). Inhibition of PKA signaling has been demonstrated to prevent both epithelial-mesenchymal transition and invasion of hepatocarcinoma cells (46). Simultaneously, no different effects or induction of PKA phosphorylation by sorafenib (10–25 mM) in Hep3B cells were also found (47). As for downregulation of PKA, this may be associated with cAMP and adenylyl cyclases, which exert tight control cell growth and survival (48). Importantly, combination treatment of Res and Sor induced significant effect on the inhibition of PKA/AMPK/eEF2K signal activation. Thus, our findings reveal that PKA/AMPK/eEF2K signal pathway may involve in the enhancement of Res and Sor combination treatment in HCC cell lines. The exact mechanism underlying the combinatory effect of Res on Sor in HCC cells needs further investigation.

Finally, we found that the combination treatment led to a significant inhibitory effect of tumor growth and tumor volume compared to treatment with either agent alone. So, our finding suggested that the combination of Res with Sor could achieve a greater therapeutic effect in HCC (15).

In summary, the results of the present study revealed that the combination treatment of Res and Sor induced more notable growth inhibition, S phase arrest, and apoptosis in the HCC cell lines than Res and Sor alone treatments. This was accompanied by the downregulation of CDC25A, CDK2, and PKA/AMPK/eEF2K signal and upregulation of cleaved-caspases in HCC cell lines (Fig. 7e). Combination of Res and Sor exhibited more inhibition in tumor growth than Res and Sor alone treatment *in vivo*. Our findings provide a novel mechanism by which Res potentiates Sor to inhibit growth and induce apoptosis in HCC cells. Our findings suggest a combination of Res and Sor therapy, which may be promising for increasing the tumor response of Sor in the future.

Acknowledgments

This work was supported by the General Research & Development Plan of Shaanxi Province (No. 2017SF-117) and Key Laboratory of Green Chemistry and Chemical Process Sub-project of Yulin (No. Yulin 2017KJJH-05).

Conflict of interest and funding

There is no conflict to declare concerning the publication of this paper. The authors have not received any funding or benefits from industry or elsewhere to conduct this study.

References

1. Williet N, Clavel L, Bourmaud A, Verot C, Bouarioua N, Roblin X, et al. Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma. *Dig Liver Dis* 2017; 49: 1043–9. doi: 10.1016/j.dld.2017.06.008

2. Cidon EU. Systemic treatment of hepatocellular carcinoma: past, present and future. *World J Hepatol* 2017; 9: 797–807. doi: 10.4254/wjh.v9.i18.797
3. Pu M, Wang J, Huang Q, Zhao G, Xia C, Shang R, et al. High MRPS23 expression contributes to hepatocellular carcinoma proliferation and indicates poor survival outcomes. *Tumor Biol* 2017; 39: 1010428317709127. doi: 10.1177/1010428317709127
4. World Health Organization. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012.2012; Available from: <http://globocan.iarc.fr/Pages/online.aspx>.
5. Giovannini C, Minguzzi M, Genovese F, Baglioni M, Gualandi A, Ravaoli M, et al. Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. *Oncotarget* 2016; 7: 39609–26. doi: 10.18632/oncotarget.9203
6. Yu Q, Liu ZY, Chen Q, Lin JS. Mcl-1 as a potential therapeutic target for human hepatocellular carcinoma. *J Huazhong Univ Sci Technolog Med Sci* 2016; 36: 494–500. doi: 10.1007/s11596-016-1614-7
7. Desai JR, Ochoa S, Prins PA, He AR. Systemic therapy for advanced hepatocellular carcinoma: an update. *J Gastrointest Oncol* 2017; 8: 243–55. doi: 10.21037/jgo.2017.02.01
8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; 359: 378–90. doi: 10.1056/NEJMoa0708857
9. Zhou J, Ng Y, Chng WJ. ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia. *Cell Mol Life Sci* 2018; 75: 3931–41. doi: 10.1007/s00018-018-2895-8
10. Kondo M, Numata K. Treatment of advanced hepatocellular carcinoma after failure of sorafenib treatment: subsequent or additional treatment interventions contribute to prolonged survival postprogression. *Gastroenterol Res Pract* 2017; 2017: 5728946. doi: 10.1155/2017/5728946
11. Moeini A, Cornella H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. *Liver Cancer* 2012; 1: 83–93. doi: 10.1159/000342405
12. Mondal A, Bennett LL. Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage. *Biomed Pharmacother* 2016; 84: 1906–14. doi: 10.1016/j.biopha.2016.10.096
13. Deng Y, Gong W, Li Q, Wu X, Wu L, Zheng X, et al. Resveratrol inhibits high glucose-induced activation of AP-1 and NF- κ B via SphK1/S1P2 pathway to attenuate mesangial cells proliferation and inflammation. *J Funct Foods* 2019; 55: 86–94. doi: 10.1016/j.jff.2019.02.014
14. Zhao DR, Jiang YS, Sun JY, Li HH, Sun XT, Zhao MM. Amelioration of 4-methylguaiacol on LPS-induced inflammation in THP-1 cells through NF- κ B/I κ B α /AP-1 and Nrf2/HO-1 signaling pathway. *J Funct Foods* 2019; 55: 95–103. doi: 10.1016/j.jff.2019.01.047
15. Dai W, Wang F, Lu J, Xia Y, He L, Chen K, et al. By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice. *Oncotarget* 2015; 6: 13703–17. doi: 10.18632/oncotarget.3800
16. Kim C, Baek SH, Um JY, Shim BS, Ahn KS. Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPepsilon and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma. *BMC Nephrol* 2016; 17: 19. doi: 10.1186/s12882-016-0233-7
17. Danz ED, Skramsted J, Henry N, Bennett JA, Keller RS. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. *Free Radic Biol Med* 2009; 46: 1589–97. doi: 10.1016/j.freeradbiomed.2009.03.011
18. Huang F, Wu XN, Chen J, Wang WX, Lu ZF. Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells. *Exp Ther Med* 2014; 7: 1611–6. doi: 10.3892/etm.2014.1662
19. Villa-Cuesta E, Boylan JM, Tatar M, Gruppuso PA. Resveratrol inhibits protein translation in hepatic cells. *PLoS One* 2011; 6: e29513. doi: 10.1371/journal.pone.0029513
20. Tameda M, Sugimoto K, Shiraki K, Inagaki Y, Ogura S, Kasai C, et al. Resveratrol sensitizes HepG2 cells to TRAIL-induced apoptosis. *Anticancer Drugs* 2014; 25: 1028–34. doi: 10.1097/CAD.000000000000128
21. Yang W, Park JJ, Yun H, Im DU, Ock S, Kim J, et al. AMP-activated protein kinase alpha2 and E2F1 transcription factor mediate doxorubicin-induced cytotoxicity by forming a positive signal loop in mouse embryonic fibroblasts and non-carcinoma cells. *J Biol Chem* 2014; 289: 4839–52. doi: 10.1074/jbc.M113.496315
22. Wei JL, Fang M, Fu ZX, Zhang SR, Guo JB, Wang R, et al. Sestrin 2 suppresses cells proliferation through AMPK/mTORC1 pathway activation in colorectal cancer. *Oncotarget* 2017; 8: 49318–28. doi: 10.18632/oncotarget.17595
23. Xia S, Ma J, Bai X, Zhang H, Cheng S, Zhang M, et al. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway. *Oncol Rep* 2014; 32: 1521–30. doi: 10.3892/or.2014.3393
24. Ferretti AC, Tonucci FM, Hidalgo F, Almada E, Larocca MC, Favre C. AMPK and PKA interaction in the regulation of survival of liver cancer cells subjected to glucose starvation. *Oncotarget* 2016; 7: 17815–28. doi: 10.18632/oncotarget.7404
25. Rose AJ, Alsted TJ, Jensen TE, Kobbero JB, Maarbjerg SJ, Jensen J, et al. A Ca(2+)-calmodulin-eEF2K-eEF2 signalling cascade, but not AMPK, contributes to the suppression of skeletal muscle protein synthesis during contractions. *J Physiol* 2009; 587: 1547–63. doi: 10.1113/jphysiol.2008.167528
26. Kaul G, Pattan G, Rafeequi T. Eukaryotic elongation factor-2 (eEF2): its regulation and peptide chain elongation. *Cell Biochem Funct* 2011; 29: 227–34. doi: 10.1002/cbf.1740
27. Garten A, Grohmann T, Kluckova K, Lavery GG, Kiess W, Penke M. Sorafenib-induced apoptosis in hepatocellular carcinoma is reversed by SIRT1. *Int J Mol Sci* 2019; 20: 4048. doi: 10.3390/ijms20164048
28. Dai J, Qichao Q, Niu K, Wang B, Li Y, Dai C, et al. Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma. *Cancer Med* 2018; 7: 5691–703. doi: 10.1002/cam4.1826
29. Zhu Y, Xu J, Hu W, Wang F, Zhou Y, Xu W, et al. TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction. *Gene* 2020; 753: 144807. doi: 10.1016/j.gene.2020
30. Liu G, Kuang S, Cao R, Wang J, Peng Q, Sun C. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP-AMPK-mTOR-SREBP1 signaling pathway. *FASEB J* 2019; 33: 10089–103. doi: 10.1096/fj.201802619RR
31. Ma X, Qiu Y, Sun Y, Zhu L, Zhao Y, Li T, et al. NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway. *Cell Death Dis* 2020; 11: 174. doi: 10.1038/s41419-020-2368-5
32. Liao PC, Ng LT, Lin LT, Richardson CD, Wang GH, Lin CC. Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular carcinoma Huh-7 cells. *J Med Food* 2010; 13: 1415–23. doi: 10.1089/jmf.2010.1126

33. Sudan S, Rupasinghe HV. Antiproliferative activity of long chain acylated esters of quercetin-3-O-glucoside in hepatocellular carcinoma HepG2 cells. *Exp Biol Med* (Maywood) 2015; 240: 1452–64. doi: 10.1177/1535370215570828
34. Wang Z, Zhao Z, Wu T, Song L, Zhang Y. Sorafenib-irinotecan sequential therapy augmented the anti-tumor efficacy of monotherapy in hepatocellular carcinoma cells HepG2. *Neoplasma* 2015; 62: 172–9. doi: 10.4149/neo_2015_022
35. Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, et al. Single agent and synergistic activity of the ‘First-in-Class’ dual PI3K/BRD4 Inhibitor SF1126 with sorafenib in hepatocellular carcinoma. *Mol Cancer Ther* 2016; 15: 2553–62. doi: 10.1158/1535-7163.MCT-15-0976
36. Bagi CM, Gebhard DF, Andresen CJ. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma. *Eur J Gastroenterol Hepatol* 2012; 24: 563–74. doi: 10.1097/MEG.0b013e328350916f
37. Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, Mccubrey JA, et al. Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. *PLoS One* 2013; 8: e65569. doi: 10.1371/journal.pone.0065569
38. Liu P, Barkley LR, Day T, Bi X, Slater DM, Alexandrow MG, et al. The Chk1-mediated S-phase checkpoint targets initiation factor Cdc45 via a Cdc25A/Cdk2-independent mechanism. *J Biol Chem* 2006; 281: 30631–44. doi: 10.1074/jbc.M602982200
39. Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB, Guan YY. Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. *Eur J Pharmacol* 2011; 670: 356–64. doi: 10.1016/j.ejphar.2011.09.031
40. White MJ, Mearthur K, Metcalf D, Lane RM, Cambier JC, Herold MJ, et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. *Cell* 2014; 159: 1549–62. doi: 10.1016/j.cell.2014.11.036
41. Prieto-Dominguez N, Ordonez R, Fernandez A, Garcia-Palomo A, Muntane J, Gonzalez-Gallego J, et al. Modulation of autophagy by sorafenib: effects on treatment response. *Front Pharmacol* 2016; 7: 151. doi: 10.3389/fphar.2016.00151
42. Rangwala F, Williams KP, Smith GR, Thomas Z, Allensworth JL, Lysterly HK, et al. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. *BMC Cancer* 2012; 12: 402. doi: 10.1186/1471-2407-12-402
43. Chen MB, Jiang Q, Liu YY, Zhang Y, He BS, Wei MX, et al. C6 ceramide dramatically increases vincristine sensitivity both in vivo and in vitro, involving AMP-activated protein kinase-p53 signaling. *Carcinogenesis* 2015; 36: 1061–70. doi: 10.1093/carcin/bgv094
44. Shi Q, Xu X, Liu Q, Luo F, Shi J, He X. MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma. *Oncol Lett* 2016; 11: 1474–80. doi: 10.3892/ol.2015.4072
45. Zhu H, Song H, Chen G, Yang X, Liu J, Ge Y, et al. eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma. *Radiother Oncol* 2017; 124: 439–47. doi: 10.1016/j.radonc.2017.04.001
46. Hu S, Wang L, Zhang X, Wu Y, Yang J, Li J. Autophagy induces transforming growth factor- β -dependent epithelial-mesenchymal transition in hepatocarcinoma cells through cAMP response element binding signalling. *J Cell Mol Med* 2018; 22: 5518–32. doi: 10.1111/jcmm.13825
47. Carr BI, Wang Z, Wang M, Cavallini A, D’Alessandro R, Refolo MG. c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. *Cancer Biol Ther* 2011; 12: 531–8. doi: 10.4161/cbt.12.6.16053
48. Zhang JZ, Lu TW, Stolerman LM, Tenner B, Yang JR, Zhang JF, et al. Phase separation of a PKA regulatory subunit controls cAMP compartmentation and oncogenic signaling. *Cell* 2020; 182: 1531–44.e15. doi: 10.1016/j.cell.2020.07.043

*Meili Gao

Department of Biological Science and Engineering
 The Key Laboratory of Biomedical Information Engineering of
 Ministry of Education
 School of Life Science and Technology
 Xi’an Jiaotong University
 Xianning West Road 28
 710049 Xi’an
 China
 Email: gml.1369@xjtu.edu.cn